➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Merck
Mallinckrodt
Moodys
Harvard Business School

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Sufentanil citrate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for sufentanil citrate and what is the scope of patent protection?

Sufentanil citrate is the generic ingredient in three branded drugs marketed by Akorn, Hospira, Watson Labs, West-ward Pharms Int, and Acelrx Pharms, and is included in five NDAs. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sufentanil citrate has ninety-two patent family members in nineteen countries.

There are nine drug master file entries for sufentanil citrate. Four suppliers are listed for this compound.

Summary for sufentanil citrate
International Patents:92
US Patents:18
Tradenames:3
Applicants:5
NDAs:5
Drug Master File Entries: 9
Finished Product Suppliers / Packagers: 4
Raw Ingredient (Bulk) Api Vendors: 25
Clinical Trials: 2
Patent Applications: 791
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in sufentanil citrate?sufentanil citrate excipients list
DailyMed Link:sufentanil citrate at DailyMed
Recent Clinical Trials for sufentanil citrate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
West China HospitalPhase 4
Fudan UniversityN/A

See all sufentanil citrate clinical trials

Pharmacology for sufentanil citrate
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for sufentanil citrate

US Patents and Regulatory Information for sufentanil citrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for sufentanil citrate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2114383 CA 2016 00007 Denmark ⤷  Free Forever Trial PRODUCT NAME: SUFENTANIL, HERUNDER SUFENTANIL SOM CITRAT; REG. NO/DATE: EU/1/15/1042/001-006 20150922
2114383 16C0010 France ⤷  Free Forever Trial PRODUCT NAME: SUFENTANIL; REGISTRATION NO/DATE: EU/1/15/1042 20150918
2114383 SPC/GB16/004 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: SUFENTANIL; REGISTERED: UK EU/1/15/1042 20150922
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Merck
Mallinckrodt
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.